Prostate Cancer Metabolism
From Biochemistry to Therapeutics
- 1st Edition - June 25, 2021
- Imprint: Academic Press
- Authors: Tomas Koltai, Stephan J. Reshkin, Fatima Baltazar, Larry Fliegel
- Language: English
- Paperback ISBN:9 7 8 - 0 - 3 2 3 - 9 0 5 2 8 - 2
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 9 0 5 5 1 - 0
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 5 7 9 2 - 9
Prostate Cancer Metabolism: From Biochemistry to Therapeutics shows the peculiarities of prostate cancer metabolism, emphasizing the targetable aspects – that have not been cons… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteProstate Cancer Metabolism: From Biochemistry to Therapeutics shows the peculiarities of prostate cancer metabolism, emphasizing the targetable aspects – that have not been considered in conventional treatment protocols. The book specifically addresses treatment of the castration-resistant stage of prostate cancer proposing many repurposed drugs and nutraceuticals to complement, not replace, standard therapies. The large body of evidence supporting these concepts makes them deserving of further research and well-designed clinical trials. It discusses lipid, cholesterol, glutamine, and glucose metabolisms and their impact on prostate cancer. Additionally, it explains how current established drugs can be repurposed to improve treatment outcomes.
The concepts set out in the book, that deal with cancer at the cellular/molecular level, help identify new avenues of research and treatments to pursue that do not affect well-being whilst offer consistent benefits. Since most practicing physicians have not studied basic biochemistry since medical school, each chapter begins with a brief review of the topic to facilitate an understanding of the metabolically-oriented approach to targeting prostate cancer. Conventional treatments are not discussed here since they are covered in textbooks and specialized updates that abound in the medical literature.
It is a valuable resource for cancer researchers, oncologists, clinicians and members of biomedical field who want to learn more about prostate cancer metabolism and how to apply recent findings in the field to bedside.
- Explains the basic aspects of prostate cancer metabolism, including its biochemistry which has a pivotal role in clinical practice
- Discusses new drugs and nutraceuticals with a metabolism-centered approach
- Offers practical bedside approach in combination with molecular and biochemical fundamentals to help readers identify and provide the best treatment to their patients
Oncologists, cancer researchers, clinicians. Urologists
- Cover image
- Title page
- Table of Contents
- Copyright
- Preface
- Acknowledgment
- Abbreviations used in this book
- Chapter 1. Introductory words: cell metabolism and systems biology
- Introduction
- Cancer and systems biology
- Understanding corticosteroids' effects in prostate cancer through systems biology
- Prostate cancer metabolism is different
- Conclusions
- Why this book?
- Chapter 2. Introduction to prostate cancer metabolism and treatment with nonconventional drugs
- Introduction
- Targeting prostate cancer metabolism
- COX2 inhibition7: celecoxib
- Pomegranate extracts
- Ellagic acid
- Statins
- Conclusion 1
- Conclusion 2
- Conclusion 3
- Conclusion 4
- Conclusion 5
- Conclusion 6
- Final conclusion on statins
- Conclusions
- Chapter 3a. The conductors of the metabolic orchestra: part I
- Introduction
- Adenosine monophosphate kinase (AMPK)
- mTORC1 (mammalian or mechanistic target of rapamycin complex 1)
- The metabolic conductors in prostate cancer
- AR–AMPK relationship
- AR–PI3K/AKT/mTORC1 relationship
- AR–AMPK–mTORC1 relationship
- Conclusions
- Chapter 3b. Phosphatase and tensin homolog deleted in chromosome 10: another metabolic regulator in prostate cancer?
- Introduction
- Metabolic functions of PTEN
- Clinical implications
- PI3K inhibitors
- Conclusions
- Chapter 4. Lipid metabolism part I: an overview
- Introduction
- Normal prostate metabolism versus prostate cancer metabolism
- Prostate cancer metabolism
- Fatty acid oxidation
- Sphingosine and sphingosine kinase 1 in prostate cancer
- Protumoral actions of sphingosine-1-phosphate
- Inhibition of S1P and SK1
- α reductases
- Discussion
- Statins and prostate cancer
- PCa progression and lipid metabolism
- Lipid peroxidation in prostate cancer
- Future perspectives
- Conclusions
- Chapter 5. Lipid metabolism part II: sphingolipids and ceramides
- Lipids: Introduction
- Fatty acids
- Phospholipase A2, AA, COX2, and cancer
- Conclusions from Table 5.1
- Lipoxygenase
- Choline phospholipid metabolism in cancer
- Sphingolipids and cancer
- Conclusions
- Chapter 6. Fatty acid synthesis and prostate cancer
- Introduction
- Synthesis of fatty acids (fatty acid synthesis pathways)
- Mechanism of apoptosis induced by FAS inhibition
- Integrating lipid synthesis in the metabolic framework
- Lipid metabolism and cancer cell membranes
- Fatty acid metabolism and prostate cancer
- Clinical implications and conclusions
- Chapter 7. Cholesterol metabolism in prostate cancer
- Introduction
- Cholesterol in the cell membrane
- Cholesterol metabolism
- Deregulation of cholesterol metabolism in prostate cancer
- Liver X receptors and prostate cancer
- Inhibiting the mevalonate pathway beyond HMG-CoA reductase
- Increased mitochondrial cholesterol
- Cholesterol's lysosomal trafficking
- Lysosomotropic compounds with anticancer activity
- Cholesterol and immunity
- Statins and cancer
- Discussion and conclusions
- Future perspectives
- Chapter 8. Glutamine metabolism in prostate cancer
- Introduction
- Glutamine and the experimental setting problems
- Glutamine metabolism
- The metabotropic glutamate receptor 1
- mGluR1 and cancer
- Environmental glutamate
- Stopping the xCT–glutamate–mGluR1 circuit
- Interfering with glutamine metabolism or its effects
- Glutaminase inhibitors
- Regulation of glutaminase
- Summary and conclusions
- Chapter 9. Carbohydrate metabolism in prostate cancer
- Introduction
- Metabolic behavior of cells in health and disease
- The lactate shuttle in prostate cancer
- Extracellular lactate as a key metabolite in prostate cancer progression
- Therapeutic implications
- Conclusions
- Chapter 10. pH and electrolytes metabolism in prostate cancer
- Introduction
- Do these concepts also apply to PCa?
- How the pH gradient is inverted in cancer in general and in prostate cancer in particular
- Timing of pH changes
- Interaction between pH and cancer progression
- Extracellular acidity has multiple protumoral effects
- How this knowledge may help achieve better therapeutic results
- Interaction between hypoxia and pH gradient inversion
- pH gradient inversion and proton exporters
- How this system works in general and in prostate cancer in particular
- Discussion
- Conclusions
- Chapter 11. Iron metabolism in prostate cancer
- Introduction
- Iron forms
- Iron in cancer
- Ferroportin-1 and hepcidin control systemic and intracellular iron levels
- Fe functions in cancer cells: ribonucleotide reductase and DNA synthesis
- Iron and metastasis
- Iron chelators in cancer treatment
- Iron metabolism linked strategies for treating cancer
- Erastin
- Iron metabolism in prostate cancer
- Other proteins involved in iron metabolism
- Therapeutic implications
- Conclusions
- Chapter 12. Androgen metabolism in castration-resistant prostate cancer
- Introduction
- Circulating androgen levels and prostate cancer risk
- Androgen metabolism
- Androgen synthesis in normal conditions
- Androgen synthesis in prostate cancer
- Androgen receptor
- Androgen receptor activation
- Androgen synthetizing machinery
- Pharmaceuticals
- The progression of prostate cancer to hormonal treatment resistance
- Mechanism of resistance to androgen blocking
- Clinical implications
- Specific androgen receptor degraders (SARDs)
- Nonclassical inhibitors of the androgen–androgen receptor axis
- Discussion
- Conclusions
- Chapter 13. Summary, discussion, and conclusions
- Introduction
- Summary
- Features specific to prostate cancer
- Highlights of all chapters
- Discussion
- Promising research on metabolic targeting of prostate cancer
- Possible drug combinations for the metabolic targeting of prostate cancer
- Conclusions and final words
- Index
- Edition: 1
- Published: June 25, 2021
- No. of pages (Paperback): 416
- No. of pages (eBook): 416
- Imprint: Academic Press
- Language: English
- Paperback ISBN: 9780323905282
- eBook ISBN: 9780323905510
- eBook ISBN: 9780443157929
TK
Tomas Koltai
Tomas Koltai is Board Certified Specialist in Medical Oncology (1985), PhD in Chemistry (1997) and Master’s in Sciences in Molecular Oncology, University of Buenos Aires (2011). He has vast experience on cancer treatment at several positions: staff oncologist, Sanatorio Mater Dei, Argentina (1985-1990); Head of Oncology, Central Hospital of the Centro Gallego de Buenos Aires (1990-2000) and Medical Director, at the same institution (2000-2002); Head of the Department of Chemotherapy, National Social Services for Retirees, Argentina (2002-2014); Head of the Department of Oncology, Social Services of the National Food Workers Union, Argentina (2010-2014) and Medical Director at the same institution (2014-2016). He has authored several seminal publications on cancer and created the new “triple-edged cancer treatment”.
Affiliations and expertise
Former Medical Director, Hospital del Centro Gallego de Buenos Aires, ArgentinaSR
Stephan J. Reshkin
Stephan Reshkin, PhD, is molecular biologist and Associate Professor at the University of Bari (Italy). Dr. Reshkin has published 108 scientific papers, several book chapters and co-authored An Innovative Approach to Understanding and Treating Cancer: Targeting pH (Elsevier, 2020). His main research interests are cancer cell and pancreatic ductal adenocarcinoma.
Affiliations and expertise
Associate Professor, Department of Biosciences, Biotechnology and Biopharmaceutics, University of Bari, ItalyFB
Fatima Baltazar
Fátima Baltazar holds a degree in Pharmaceutical Sciences by the University of Coimbra (Portugal, 1991), a PhD by the University of Hull (UK, 1998) and has postdoctoral experience at the University of Minho (Portugal, 1998-2003). She is currently Associate Professor at the Medical School of University of Minho (Portugal). Fatima joined ICVS (Life and Health Sciences Research Institute) team in 2004 and she is currently Principal Investigator and Coordinator of the Surgical Sciences Research Domain (SSRD). She started her research on the Cancer field in 2005 and, in the last years, Fatima’s main research interest has been on cancer metabolism, focusing on the discovery of new prognostic metabolic biomarkers and cancer therapeutic targets, using human samples and suitable in vitro and in vivo cancer models. Fátima has published 104 international peer-reviewed research articles, 8 book chapters and she is also (co-)inventor on two national patent applications.
Affiliations and expertise
Associate Professor, Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, PortugalLF
Larry Fliegel
Research in Dr. Fliegel’s laboratory investigates membrane proteins’ function, how intracellular pH is regulated and the role of Na+/H+ exchanger in human disease, especially heart disease and breast cancer. The work is funded by CIHR and other sources. Dr. Fliegel has published over 150 publications in numerous journals including J. Biological Chemistry, J. Molecular and Cellular Cardiology, Hypertension, Cancer Research, Basic Research in Cardiology and others. He has authored two books and served on several editorial boards of Journals and grant panels such as CIHR. His awards include a Killam Annual Professor Award (2009-10), a Tier one Basic Science Mentoring Award (2013), McCalla Research Professorship Award (2007) and Alberta Heritage Foundation for Medical Research Scientist Award (2006-2013).
Affiliations and expertise
Professor, Associate Chair, Department of Biochemistry, Faculty of Medicine, University of Alberta, CanadaRead Prostate Cancer Metabolism on ScienceDirect